Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin

Journal of Theoretical Biology

Volumn 282, Issue 1, 2011, Pages 80-92

  Goutelle, Sylvain ^a,b   Bourguignon, Laurent ^a,b   Jelliffe, Roger W ^c   Conte, John E ^d,e   Maire, Pascal ^a,b  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e American Health Sciences   (United States)

Author keywords

Mathematical model; Pharmacodynamics; Pharmacokinetics; Simulations; Tuberculosis

Indexed keywords

RIFAMPICIN;

DISEASE TREATMENT; MICROBIAL ACTIVITY; NUMERICAL MODEL; TUBERCULOSIS;

ANTIBACTERIAL ACTIVITY; ARTICLE; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFICACY; EPITHELIUM; HUMAN; IMMUNE RESPONSE; LATENT TUBERCULOSIS; LUNG ALVEOLUS CELL; LUNG ALVEOLUS MACROPHAGE; LUNG TUBERCULOSIS; MATHEMATICAL MODEL; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; SIMULATION;

ANIMALS; ANTITUBERCULAR AGENTS; MICE; MODELS, THEORETICAL; RIFAMPIN; TUBERCULOSIS, PULMONARY;

BACTERIA (MICROORGANISMS);

EID: 79957790326     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2011.05.013     Document Type: Article

References (65)

1. Allen B.W., Mitchison D.A. Counts of viable tubercle bacilli in sputum related to smear and culture gradings. Med. Lab. Sci. 1992, 49:94-98.
2. Antia R., Koella J.C., Perrot V. Models of the within-host dynamics of persistent mycobacterial infections. Proc. R. Soc. London B 1996, 263:257-263.
3. Balaban N.Q., Merrin J., Chait R., Kowalik L., Leibler S. Bacterial persistence as a phenotypic switch. Science 2004, 305:1622-1625.
4. Bonhoeffer S., May R.M., Shaw G.M., Nowak M.A. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. USA 1997, 94:6971-6976.
5. Burman W.J. The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review. Am. J. Med. Sci. 1997, 313:355-363.
6. Center for Disease Control and Prevention Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs. MMWR-Morb. Mortal. Wkly. Rep. 2006, 55:301-305.
7. Chan C.Y., Au-Yeang C., Yew W.W., Hui M., Cheng A.F. Postantibiotic effects of antituberculosis agents alone and in combination. Antimicrob. Agents Chemother. 2001, 45:3631-3634.
8. Chan S.L., Yew W.W., Ma W.K., Girling D.J., Aber V.R., Felmingham D., Allen B.W., Mitchison D.A. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuberc. Lung Dis. 1992, 73:33-38.
9. Chanwong S., Maneekarn N., Makonkawkeyoon L., Makonkawkeyoon S. Intracellular growth and drug susceptibility of Mycobacterium tuberculosis in macrophages. Tuberculosis (Edinburgh) 2007, 87:130-133.
10. Connolly L.E., Edelstein P.H., Ramakrishnan L. Why is long-term therapy required to cure tuberculosis?. PLoS Med. 2007, 4:e120.
11. Conte J.E., Golden J.A., Kipps J.E., Lin E.T., Zurlinden E. Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. Clin. Pharmacokinet. 2004, 43:395-404.
12. Davies G.R. Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity. Tuberculosis (Edinburgh) 2010, 90:171-176.
13. Davies G.R., Brindle R., Khoo S.H., Aarons L.J. Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrob. Agents Chemother. 2006, 50:3154-3156.
14. Diacon A.H., Patientia R.F., Venter A., van Helden P.D., Smith P.J., McIlleron H., Maritz J.S., Donald P.R. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 2007, 51:2994-2996.
15. Donald P.R., Diacon A.H. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis (Edinburgh) 2008, 88(Suppl. 1):S75-S83.
16. Drusano G.L., Sgambati N., Eichas A., Brown D.L., Kulawy R., Louie A. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. MBio 2010, 1.
17. Ehlers S. Lazy, dynamic or minimally recrudescent? On the elusive nature and location of the mycobacterium responsible for latent tuberculosis. Infection 2009, 37:87-95.
18. Fang X., Wallqvist A., Reifman J. A systems biology framework for modeling metabolic enzyme inhibition of Mycobacterium tuberculosis. BMC Syst. Biol. 2009, 3:92.
19. Gandhi N.R., Moll A., Sturm A.W., Pawinski R., Govender T., Lalloo U., Zeller K., Andrews J., Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1575-1580.
20. Gosling R.D., Uiso L.O., Sam N.E., Bongard E., Kanduma E.G., Nyindo M., Morris R.W., Gillespie S.H. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 2003, 168:1342-1345.
21. Goutelle S., Bourguignon L., Maire P.H., Van Guilder M., Conte J.E., Jelliffe R.W. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob. Agents Chemother. 2009, 53:2974-2981.
22. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob. Agents Chemother. 2010, 54:1484-1491.
23. Gumbo T., Louie A., Deziel M.R., Drusano G.L. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob. Agents Chemother. 2005, 49:3178-3181.
24. Gumbo T., Louie A., Deziel M.R., Parsons L.M., Salfinger M., Drusano G.L. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 2004, 190:1642-1651.
25. Gumbo T., Louie A., Liu W., Brown D., Ambrose P.G., Bhavnani S.M., Drusano G.L. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob. Agents Chemother. 2007, 51:2329-2336.
26. Gumbo T., Louie A., Liu W., Ambrose P.G., Bhavnani S.M., Brown D., Drusano G.L. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J. Infect. Dis. 2007, 195:194-201.
27. Gumbo T., Louie A., Deziel M.R., Liu W., Parsons L.M., Salfinger M., Drusano G.L. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 2007, 51:3781-3788.
28. Gupta U.D., Katoch V.M. Animal models of tuberculosis. Tuberculosis (Edinburgh) 2005, 85:277-293.
29. Jaffuel D., Demoly P., Gougat C., Mautino G., Bousquet J., Mathieu M. Rifampicin is not an activator of the glucocorticoid receptor in A549 human alveolar cells. Mol. Pharmacol. 1999, 55:841-846.
30. Jayaram R., Gaonkar S., Kaur P., Suresh B.L., Mahesh B.N., Jayashree R., Nandi V., Bharat S., Shandil R.K., Kantharaj E., Balasubramanian V. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 2003, 47:2118-2124.
31. Jayaram R., Shandil R.K., Gaonkar S., Kaur P., Suresh B.L., Mahesh B.N., Jayashree R., Nandi V., Bharath S., Kantharaj E., Balasubramanian V. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 2004, 48:2951-2957.
32. Jindani A., Dore C.J., Mitchison D.A. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 2003, 167:1348-1354.
33. Jindani A., Aber V.R., Edwards E.A., Mitchison D.A. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 1980, 121:939-949.
34. Keren I., Shah D., Spoering A., Kaldalu N., Lewis K. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J. Bacteriol. 2004, 186:8172-8180.
35. Kirschner D.E., Young D., Flynn J.L. Tuberculosis: global approaches to a global disease. Curr. Opin. Biotechnol. 2010, 21.
36. Lewin S.R., Ribeiro R.M., Walters T., Lau G.K., Bowden S., Locarnini S., Perelson A.S. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001, 34:1012-1020.
37. Lipsitch M., Levin B.R. Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int. J. Tuberc. Lung Dis. 1998, 2:187-199.
38. Magombedze G., Garira W., Mwenje E. Mathematical modeling of chemotherapy of human TB infection. J. Biol. Systems 2006, 14:509-553.
39. Manca C., Tsenova L., Barry C.E., Bergtold A., Freeman S., Haslett P.A., Musser J.M., Freedman V.H., Kaplan G. Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J. Immunol. 1999, 162:6740-6746.
40. Marino S., Kirschner D.E. The human immune response to Mycobacterium tuberculosis in lung and lymph node. J. Theor. Biol. 2004, 227:463-486.
41. Marino S., Myers A., Flynn J.L., Kirschner D.E. TNF and IL-10 are major factors in modulation of the phagocytic cell environment in lung and lymph node in tuberculosis: a next-generation two-compartmental model. J. Theor. Biol. 2010, 265:586-598.
42. Mitchison D.A. Basic mechanisms of chemotherapy. Chest 1979, 76:771-781.
43. Mitchison D.A. Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease. Soc. Appl. Bacteriol. Symp. Ser. 1996, 25:72S-80S.
44. Mitchison D.A. The diagnosis and therapy of tuberculosis during the past 100 years. Am. J. Respir. Crit. Care Med. 2005, 171:699-706.
45. Mitchison D.A., Jindani A., Davies G.R., Sirgel F. Isoniazid activity is terminated by bacterial persistence. J. Infect. Dis. 2007, 195:1871-1872. (author reply 1872-3).
46. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107.
47. North R.J., Izzo A.A. Mycobacterial virulence. Virulent strains of Mycobacteria tuberculosis have faster in vivo doubling times and are better equipped to resist growth-inhibiting functions of macrophages in the presence and absence of specific immunity. J. Exp. Med. 1993, 177:1723-1733.
48. Nuermberger E., Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur. J. Clin. Microbiol. Infect. Dis. 2004, 23:243-255.
49. Pargal A., Rani S. Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. Int. J. Tuberc. Lung Dis. 2001, 5:70-79.
50. Paul S., Laochumroonvorapong P., Kaplan G. Comparable growth of virulent and avirulent Mycobacterium tuberculosis in human macrophages in vitro. J. Infect. Dis. 1996, 174:105-112.
51. Peloquin C. What is the 'right' dose of rifampin?. Int. J. Tuberc. Lung Dis. 2003, 7:3-5.
52. Peloquin C.A., Jaresko G.S., Yong C.L., Keung A.C., Bulpitt A.E., Jelliffe R.W. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother. 1997, 41:2670-2679.
53. Ruslami R., Nijland H.M., Alisjahbana B., Parwati I., van Crevel R., Aarnoutse R.E. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 2007, 51:2546-2551.
54. Salomon J.A., Lloyd-Smith J.O., Getz W.M., Resch S., Sanchez M.S., Porco T.C., Borgdorff M.W. Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med. 2006, 3:e273.
55. Segovia-Juarez J.L., Ganguli S., Kirschner D. Identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model. J. Theor. Biol. 2004, 231:357-376.
56. Silver R.F., Li Q., Ellner J.J. Expression of virulence of Mycobacterium tuberculosis within human monocytes: virulence correlates with intracellular growth and induction of tumor necrosis factor alpha but not with evasion of lymphocyte-dependent monocyte effector functions. Infect. Immun. 1998, 66:1190-1199.
57. Sirgel F.A., Botha F.J., Parkin D.P., Van De Wal B.W., Donald P.R., Clark P.K., Mitchison D.A. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J. Antimicrob. Chemother. 1993, 32:867-875.
58. Sirgel F.A., Fourie P.B., Donald P.R., Padayatchi N., Rustomjee R., Levin J., Roscigno G., Norman J., McIlleron H., Mitchison D.A. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 2005, 172:128-135.
59. Sirgel F.A., Donald P.R., Odhiambo J., Githui W., Umapathy K.C., Paramasivan C.N., Tam C.M., Kam K.M., Lam C.W., Sole K.M., Mitchison D.A. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J. Antimicrob. Chemother. 2000, 45:859-870.
60. Tauber S.C., Nau R. Immunomodulatory properties of antibiotics. Curr. Mol. Pharmacol. 2008, 1:68-79.
61. Tsiang M., Rooney J.F., Toole J.J., Gibbs C.S. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999, 29:1863-1869.
62. Wallis R.S., Palaci M., Eisenach K. Persistence, not resistance, is the cause of loss of isoniazid effect. J. Infect. Dis. 2007, 195:1870-1871. (author reply 1872-3).
63. Wigginton J.E., Kirschner D. A model to predict cell-mediated immune regulatory mechanisms during human infection with Mycobacterium tuberculosis. J. Immunol. 2001, 166:1951-1967.
64. World Health Organization Global Tuberculosis Control: Epidemiology, Strategy, Financing 2009, World Health Organization, Geneva.
65. Young D., Stark J., Kirschner D. Systems biology of persistent infection: tuberculosis as a case study. Nat. Rev. Microbiol. 2008, 6:520-528.